114 related articles for article (PubMed ID: 20404010)
1. Bezafibrate mildly stimulates ketogenesis and fatty acid metabolism in hypertriglyceridemic subjects.
Tremblay-Mercier J; Tessier D; Plourde M; Fortier M; Lorrain D; Cunnane SC
J Pharmacol Exp Ther; 2010 Jul; 334(1):341-6. PubMed ID: 20404010
[TBL] [Abstract][Full Text] [Related]
2. Activation of peroxisome proliferator-activated receptor-α (PPARα) suppresses postprandial lipidemia through fatty acid oxidation in enterocytes.
Kimura R; Takahashi N; Murota K; Yamada Y; Niiya S; Kanzaki N; Murakami Y; Moriyama T; Goto T; Kawada T
Biochem Biophys Res Commun; 2011 Jun; 410(1):1-6. PubMed ID: 21640707
[TBL] [Abstract][Full Text] [Related]
3. PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes.
Seo YS; Kim JH; Jo NY; Choi KM; Baik SH; Park JJ; Kim JS; Byun KS; Bak YT; Lee CH; Kim A; Yeon JE
J Gastroenterol Hepatol; 2008 Jan; 23(1):102-9. PubMed ID: 18171348
[TBL] [Abstract][Full Text] [Related]
4. Metformin treatment of rats with diet-induced overweight and hypertriglyceridemia decreases plasma triglyceride concentrations, while decreasing triglyceride and increasing ketone body output by the isolated perfused liver.
Tessari P; Tiengo A
Acta Diabetol; 2008 Sep; 45(3):143-5. PubMed ID: 18357405
[TBL] [Abstract][Full Text] [Related]
5. Eicosapentaenoic acid decreases postprandial beta-hydroxybutyrate and free fatty acid responses in healthy young and elderly.
Plourde M; Tremblay-Mercier J; Fortier M; Pifferi F; Cunnane SC
Nutrition; 2009 Mar; 25(3):289-94. PubMed ID: 19036560
[TBL] [Abstract][Full Text] [Related]
6. Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome.
Rosenson RS; Wolff DA; Huskin AL; Helenowski IB; Rademaker AW
Diabetes Care; 2007 Aug; 30(8):1945-51. PubMed ID: 17483155
[TBL] [Abstract][Full Text] [Related]
7. In contrast with docosahexaenoic acid, eicosapentaenoic acid and hypolipidaemic derivatives decrease hepatic synthesis and secretion of triacylglycerol by decreased diacylglycerol acyltransferase activity and stimulation of fatty acid oxidation.
Berge RK; Madsen L; Vaagenes H; Tronstad KJ; Göttlicher M; Rustan AC
Biochem J; 1999 Oct; 343 Pt 1(Pt 1):191-7. PubMed ID: 10493929
[TBL] [Abstract][Full Text] [Related]
8. Effects of bezafibrate on insulin sensitivity and insulin secretion in non-obese Japanese type 2 diabetic patients.
Taniguchi A; Fukushima M; Sakai M; Tokuyama K; Nagata I; Fukunaga A; Kishimoto H; Doi K; Yamashita Y; Matsuura T; Kitatani N; Okumura T; Nagasaka S; Nakaishi S; Nakai Y
Metabolism; 2001 Apr; 50(4):477-80. PubMed ID: 11288046
[TBL] [Abstract][Full Text] [Related]
9. Effect of bezafibrate on metabolic profiles in non-insulin-dependent diabetes mellitus.
Alberti KG; Jones IR; Laker MF; Swai AB; Taylor R
J Cardiovasc Pharmacol; 1990; 16 Suppl 9():S21-4; discussion S24-5. PubMed ID: 1710741
[TBL] [Abstract][Full Text] [Related]
10. Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin Alone and in Combination Treatment.
Cortellaro M; Cofrancesco E; Boschetti C; Cortellaro F; Mancini M; Mariani M; Paoletti R
Thromb Haemost; 2000 Apr; 83(4):549-53. PubMed ID: 10780315
[TBL] [Abstract][Full Text] [Related]
11. Hormonal regulation of ketone-body metabolism in man.
Alberti KG; Johnston DG; Gill A; Barnes AJ; Orskov H
Biochem Soc Symp; 1978; (43):163-82. PubMed ID: 749914
[TBL] [Abstract][Full Text] [Related]
12. Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men.
Risérus U; Sprecher D; Johnson T; Olson E; Hirschberg S; Liu A; Fang Z; Hegde P; Richards D; Sarov-Blat L; Strum JC; Basu S; Cheeseman J; Fielding BA; Humphreys SM; Danoff T; Moore NR; Murgatroyd P; O'Rahilly S; Sutton P; Willson T; Hassall D; Frayn KN; Karpe F
Diabetes; 2008 Feb; 57(2):332-9. PubMed ID: 18024853
[TBL] [Abstract][Full Text] [Related]
13. Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease.
Tenenbaum A; Motro M; Fisman EZ; Schwammenthal E; Adler Y; Goldenberg I; Leor J; Boyko V; Mandelzweig L; Behar S
Circulation; 2004 May; 109(18):2197-202. PubMed ID: 15123532
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of peroxisome proliferator-activated receptor activators on the mRNA levels of genes involved in lipid metabolism in primary human monocyte-derived macrophages.
Cabrero A; Cubero M; Llaverías G; Jové M; Planavila A; Alegret M; Sánchez R; Laguna JC; Carrera MV
Metabolism; 2003 May; 52(5):652-7. PubMed ID: 12759900
[TBL] [Abstract][Full Text] [Related]
15. Effect of heat stress and bezafibrate on mitochondrial beta-oxidation: comparison between cultured cells from normal and mitochondrial fatty acid oxidation disorder children using in vitro probe acylcarnitine profiling assay.
Li H; Fukuda S; Hasegawa Y; Kobayashi H; Purevsuren J; Mushimoto Y; Yamaguchi S
Brain Dev; 2010 May; 32(5):362-70. PubMed ID: 19589653
[TBL] [Abstract][Full Text] [Related]
16. The metabolic syndrome and the hepatic fatty acid drainage hypothesis.
Berge RK; Tronstad KJ; Berge K; Rost TH; Wergedahl H; Gudbrandsen OA; Skorve J
Biochimie; 2005 Jan; 87(1):15-20. PubMed ID: 15733731
[TBL] [Abstract][Full Text] [Related]
17. Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate.
Tenenbaum A; Fisman EZ; Boyko V; Benderly M; Tanne D; Haim M; Matas Z; Motro M; Behar S
Arch Intern Med; 2006 Apr; 166(7):737-41. PubMed ID: 16606809
[TBL] [Abstract][Full Text] [Related]
18. Effects of bezafibrate on lipoprotein subclasses and inflammatory markers in patients with hypertriglyceridemia--a nuclear magnetic resonance study.
Ikewaki K; Noma K; Tohyama J; Kido T; Mochizuki S
Int J Cardiol; 2005 Jun; 101(3):441-7. PubMed ID: 15907413
[TBL] [Abstract][Full Text] [Related]
19. A moderate increase in carnitine palmitoyltransferase 1a activity is sufficient to substantially reduce hepatic triglyceride levels.
Stefanovic-Racic M; Perdomo G; Mantell BS; Sipula IJ; Brown NF; O'Doherty RM
Am J Physiol Endocrinol Metab; 2008 May; 294(5):E969-77. PubMed ID: 18349115
[TBL] [Abstract][Full Text] [Related]
20. Bezafibrate, an anti-hypertriglyceridemic drug, attenuates vascular hyperresponsiveness and elevated blood pressure in fructose-induced hypertensive rats.
Si X; Webb RC; Richey JM
Can J Physiol Pharmacol; 1999 Oct; 77(10):755-62. PubMed ID: 10588479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
